BioCentury | May 5, 2014
Product Development

Dollars and sense

...Monteleone. He declined to disclose how or when Nogra obtained rights to GED-0301. Nogra (formerly Giuliani S.p.A....
BioCentury | Apr 28, 2014
Company News

Celgene, Nogra Pharma deal

...GED-0301 to treat moderate to severe Crohn's disease (CD) and other gastrointestinal indications. Nogra (formerly Giuliani S.p.A....
BioCentury | Apr 25, 2014
Top Story

Celgene fronts $710M for Crohn's compound

...commercialize GED-0301 to treat moderate to severe Crohn's disease and other gastrointestinal indications. Nogra (formerly Giuliani S.p.A....
BioCentury | Apr 2, 2012
Clinical News

Lialda mesalamine: Phase III data

...to the product in the U.S., Canada, Europe (except Italy) and the Pacific Rim from Giuliani...
...MMX technology from Cosmo Pharmaceuticals S.p.A. (SIX:COPN; Lainate, Italy). Shire plc (LSE:SHP; NASDAQ:SHPGY), Dublin, Ireland Giuliani S.p.A....
BioCentury | Jul 25, 2011
Clinical News

Lialda mesalamine regulatory update

...to the product in the U.S., Canada, Europe (except Italy) and the Pacific Rim from Giuliani...
...while Mochida has exclusive rights in Japan from Shire. Shire plc (LSE:SHP; NASDAQ:SHPGY), Dublin, Ireland Giuliani S.p.A....
BioCentury | May 9, 2011
Clinical News

Mezavant mesalamine regulatory update

...to the product in the U.S., Canada, Europe (except Italy) and the Pacific Rim from Giuliani...
...while Mochida has exclusive rights in Japan from Shire. Shire plc (LSE:SHP; NASDAQ:SHPGY), Dublin, Ireland Giuliani S.p.A....
BioCentury | Nov 8, 2010
Politics, Policy & Law

Much Ado about DoJ

...and Holman wrote in their amicus brief. Michael Samardzija, counsel at law firm Bracewell & Giuliani...
BioCentury | Jul 5, 2010
Politics, Policy & Law

Process patent reset

...but the possibility is there," Meyers said. Michael Samardzija, counsel in law firm Bracewell & Giuliani's...
BioCentury | Apr 5, 2010
Politics, Policy & Law

Bracketing the BRCA Appeal

...so much more familiar with patent law." Michael Samardzija, counsel at law firm Bracewell & Giuliani...
BioCentury | May 11, 2009
Company News

Shire, Takeda, Teva deal

...to the compound in the U.S., Canada, Europe (except Italy) and the Pacific Rim from Giuliani S.p.A....
Items per page:
1 - 10 of 45
BioCentury | May 5, 2014
Product Development

Dollars and sense

...Monteleone. He declined to disclose how or when Nogra obtained rights to GED-0301. Nogra (formerly Giuliani S.p.A....
BioCentury | Apr 28, 2014
Company News

Celgene, Nogra Pharma deal

...GED-0301 to treat moderate to severe Crohn's disease (CD) and other gastrointestinal indications. Nogra (formerly Giuliani S.p.A....
BioCentury | Apr 25, 2014
Top Story

Celgene fronts $710M for Crohn's compound

...commercialize GED-0301 to treat moderate to severe Crohn's disease and other gastrointestinal indications. Nogra (formerly Giuliani S.p.A....
BioCentury | Apr 2, 2012
Clinical News

Lialda mesalamine: Phase III data

...to the product in the U.S., Canada, Europe (except Italy) and the Pacific Rim from Giuliani...
...MMX technology from Cosmo Pharmaceuticals S.p.A. (SIX:COPN; Lainate, Italy). Shire plc (LSE:SHP; NASDAQ:SHPGY), Dublin, Ireland Giuliani S.p.A....
BioCentury | Jul 25, 2011
Clinical News

Lialda mesalamine regulatory update

...to the product in the U.S., Canada, Europe (except Italy) and the Pacific Rim from Giuliani...
...while Mochida has exclusive rights in Japan from Shire. Shire plc (LSE:SHP; NASDAQ:SHPGY), Dublin, Ireland Giuliani S.p.A....
BioCentury | May 9, 2011
Clinical News

Mezavant mesalamine regulatory update

...to the product in the U.S., Canada, Europe (except Italy) and the Pacific Rim from Giuliani...
...while Mochida has exclusive rights in Japan from Shire. Shire plc (LSE:SHP; NASDAQ:SHPGY), Dublin, Ireland Giuliani S.p.A....
BioCentury | Nov 8, 2010
Politics, Policy & Law

Much Ado about DoJ

...and Holman wrote in their amicus brief. Michael Samardzija, counsel at law firm Bracewell & Giuliani...
BioCentury | Jul 5, 2010
Politics, Policy & Law

Process patent reset

...but the possibility is there," Meyers said. Michael Samardzija, counsel in law firm Bracewell & Giuliani's...
BioCentury | Apr 5, 2010
Politics, Policy & Law

Bracketing the BRCA Appeal

...so much more familiar with patent law." Michael Samardzija, counsel at law firm Bracewell & Giuliani...
BioCentury | May 11, 2009
Company News

Shire, Takeda, Teva deal

...to the compound in the U.S., Canada, Europe (except Italy) and the Pacific Rim from Giuliani S.p.A....
Items per page:
1 - 10 of 45